|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
03-19-2010, 12:26 PM
|
|||
|
|||
Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoint
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with ...
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Phase 3 trial of Nexavar in first-line advanced NSCLC fails to meet primary endpoint | cancerfr | Adrenocortical Carcinoma | 0 | 06-15-2010 08:06 PM |
| Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC | cancerfr | Adrenocortical Carcinoma | 0 | 06-14-2010 03:56 PM |
| Delcath Systems' phase-III NCI-led multi-center trial meets primary endpoint | cancerfr | Melanoma | 0 | 04-25-2010 03:46 AM |
| Delcath Phase III Trial Results Exceed Primary Endpoint Expectations | cancerfr | Melanoma | 0 | 04-22-2010 06:10 PM |
| Delcath Phase III Trial Results Exceed Primary Endpoint Expectations | cancerfr | Melanoma | 0 | 04-21-2010 09:55 PM |
Linear Mode
